A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
96
Participants
Timeline
Start Date
December 25, 2023
Primary Completion Date
August 2, 2024
Study Completion Date
September 29, 2024
Conditions
Healthy
Interventions
DRUG
HSK39297
50-600mg
Trial Locations (1)
Unknown
Beijing Tongren Hospital, Beijing
All Listed Sponsors
lead
Haisco Pharmaceutical Group Co., Ltd.
INDUSTRY
NCT06350279 - A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects | Biotech Hunter | Biotech Hunter